Bexagliflozin vs Ertugliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Bexagliflozin · Brenzavvy

Marketed by Theracos and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT02558296 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.

Next expected readout: March 2029 · NCT07547878 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)

Result source: NCT02769481

Ertugliflozin · Steglatro

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01986881 · Phase 3 · completed

This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.

Next expected readout: January 2028 · NCT07621380 (registry estimate)

Reported efficacy

Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)

Result source: NCT01986881

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBexagliflozinErtugliflozin
HbA1c, change-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825
Body weight, change (kg)-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-3.8 vs -1.3−2.5 vs placebo15 mg · wk 208 · n 2746NCT01986881
43 other results
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
HbA1c below 7%—Not reported20% vs 16.5%+3.5 vs placebo15 mg · wk 260 · n 529NCT01986881
43 other results
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 28.2% vs 15.5% 15 mg · wk 18 · n 2520 · Phase 3 · secondary NCT01986881
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
Fasting plasma glucose, change-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825
3-point MACE (% with event)—Not reported—Not posted · NCT03717194

HbA1c, change

Bexagliflozin
-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Ertugliflozin
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825

Body weight, change (kg)

Bexagliflozin
-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Ertugliflozin
-3.8 vs -1.3−2.5 vs placebo15 mg · wk 208 · n 2746NCT01986881
43 other results
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.3 vs -0.4 15 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110

HbA1c below 7%

Bexagliflozin
—Not reported
Ertugliflozin
20% vs 16.5%+3.5 vs placebo15 mg · wk 260 · n 529NCT01986881
43 other results
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 28.2% vs 15.5% 15 mg · wk 18 · n 2520 · Phase 3 · secondary NCT01986881
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825

Fasting plasma glucose, change

Bexagliflozin
-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Ertugliflozin
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825

3-point MACE (% with event)

Bexagliflozin
—Not reported
Ertugliflozin
—Not posted · NCT03717194
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Bexagliflozin: 6 of 6 rows · Ertugliflozin: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBexagliflozin
Rows use multiple source trials
Ertugliflozin
Rows use multiple source trials
SBP
absolute change · mmHg
-5.03 vs 2.04 placebo mmHg @ 24wk20 mga,b,c
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
2 other source trials
-4.23 vs -1.9 Sitagliptin mmHg @ 24wk
NCT03115112 · Phase 3
-10.14 vs -7.51 placebo mmHg @ 24wk20 mg
NCT02836873 · Phase 3
-3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mgd,a,b,c
NCT02226003 · Phase 3 · combination
show 1 more dose
-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Seated SBP
absolute change · mmHg
-13.48 vs -6.95 Glimepiride mmHg @ 60wke,f,g
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-3.46 vs 2.72 placebo mmHg @ 312wk15 mgd,e,f,g
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
1.28 vs 2.72 placebo mmHg @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
3.9%20 mgh
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
15.5%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.8%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
11.4%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.3%
NCT03115112 · Phase 3
3.2%20 mg
NCT02836873 · Phase 3
9.2%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
6.9%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
—15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.6%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.8%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
22.9%15 mg
NCT01999218 · Phase 3
24.3%5 mg
NCT01999218 · Phase 3
12.5%15 mg
NCT02099110 · Phase 3
9.6%5 mg
NCT02099110 · Phase 3
11%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
9.1%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
7.7%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
3.2%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
9%15 mg
NCT01986855 · Phase 3
8.2%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.3%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
4.1%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
0%
NCT03416270 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
7.7%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
5.1%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
39.3%
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.8%20 mgh
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
1.4%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
—20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.6%
NCT03115112 · Phase 3
0.6%20 mg
NCT02836873 · Phase 3
—20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
—15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.7%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%15 mg
NCT02033889 · Phase 3
0.5%5 mg
NCT02033889 · Phase 3
1.6%15 mg
NCT01999218 · Phase 3
2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
1.2%5 mg
NCT02099110 · Phase 3
0.8%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
1.2%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
0.6%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
0.6%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
—15 mg + 100 mg
NCT02226003 · Phase 3 · combination
—5 mg + 100 mg
NCT02226003 · Phase 3 · combination
0%15 mg
NCT01986855 · Phase 3
0.6%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0.6%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
1.2%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
—
NCT03416270 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Serious AEs
33%20 mgh
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.7%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.7%
NCT03115112 · Phase 3
7%20 mg
NCT02836873 · Phase 3
2.6%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
0%Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
7.3%15 mgi
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
7.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.9%15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.9%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.9%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.1%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.8%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
7.4%15 mg
NCT01999218 · Phase 3
9.2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
4.8%5 mg
NCT02099110 · Phase 3
4.9%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
3.7%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
—15 mg
NCT02036515 · Phase 3
2%15 mg
NCT02036515 · Phase 3 · combination
—5 mg
NCT02036515 · Phase 3
8.3%5 mg
NCT02036515 · Phase 3 · combination
3.1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
19.4%15 mg
NCT01986855 · Phase 3
16.5%5 mg
NCT01986855 · Phase 3
3.8%15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
3.2%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
4.5%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.9%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
5.3%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
17.6%
NCT03416270 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
3.6%5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
1.8%25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%
NCT04167761 · Phase 1 · registry result, not featured evidence
0%15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
20 mgh
hypoglycaemia 42% (placebo 43.4%)
urinary tract infection 11.3% (placebo 10.6%)
upper respiratory tract infection 9.9% (placebo 9.3%)
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
hypoglycemia 16.9%
nasopharyngitis 13.6%
urinary tract infection 11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20 mg
nasopharyngitis 5.7% (placebo 8.2%)
polydipsia 3.2% (placebo 2.5%)
polyuria 3.2% (placebo 3.8%)
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
20 mg
polyuria 7.2% (placebo 2.9%)
urinary tract infection 5.1% (placebo 2.9%)
abdominal pain 3.6% (placebo 7.2%)
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 7.9%
urinary tract infection 3.7%
hypoglycemia 3.1%
NCT03115112 · Phase 3
20 mg
hypoglycaemia 25.5% (placebo 25.8%)
polyuria 7.6% (placebo 4.5%)
nasopharyngitis 7% (placebo 8.4%)
NCT02836873 · Phase 3
20 mg
hypoglycemia 5.3% (placebo 1.4%)
dysuria 3.9% (placebo 1.4%)
nasopharyngitis 3.9% (placebo 4.2%)
NCT02390050 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 5.6% (placebo 4.2%)
pharyngitis 4.2% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT02390050 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 6.9% (placebo 4.2%)
diarrhea 2.8% (placebo 2.8%)
dizziness 2.8% (placebo 1.4%)
NCT02390050 · Phase 2 · registry result, not featured evidence
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 6.3%
gastrointestinal sounds abnormal 6.3%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
laceration 6.3%
presyncope 6.3%
diarrhea 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
dizziness 4.2%
headache 4.2%
nasal congestion 4.2%
NCT02820298 · Phase 1 · registry result, not featured evidence
chest discomfort 4.3%
dizziness 4.3%
headache 4.3%
NCT02820298 · Phase 1 · registry result, not featured evidence
15 mgi
hypoglycaemia 30.3% (placebo 31.4%)
nasopharyngitis 3.5% (placebo 3.2%)
upper respiratory tract infection 2.7% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 44 more results
15 mg
hypoglycaemia 16.8% (placebo 31.4%)
nasopharyngitis 4.4% (placebo 3.2%)
dizziness 3.5% (placebo 1.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 31.1% (placebo 31.4%)
urinary tract infection 9.5% (placebo 2%)
nasopharyngitis 7.4% (placebo 3.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 5.6% (placebo 31.4%)
urinary tract infection 1.9% (placebo 2%)
back pain 0% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 29% (placebo 31.4%)
dizziness 2.3% (placebo 1.2%)
upper respiratory tract infection 2.3% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 13% (placebo 31.4%)
hypertension 4% (placebo 0.6%)
hyperglycaemia 3% (placebo 1.7%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 32.2% (placebo 31.4%)
urinary tract infection 9.3% (placebo 2%)
upper respiratory tract infection 7.2% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 5.5% (placebo 31.4%)
back pain 3.6% (placebo 0.6%)
hypertension 3.6% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15 mg
nasopharyngitis 7.2% (placebo 3.9%)
upper respiratory tract infection 6.6% (placebo 5.9%)
urinary tract infection 6.6% (placebo 12.4%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
urinary tract infection 8.3% (placebo 12.4%)
vulvovaginal mycotic infection 7.7% (placebo 1.3%)
constipation 7.1% (placebo 2.6%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
upper respiratory tract infection 10.2% (placebo 15.8%)
back pain 9.8% (placebo 4.8%)
hypoglycaemia 8.8% (placebo 20.6%)
NCT02033889 · Phase 3
5 mg
upper respiratory tract infection 11.1% (placebo 15.8%)
headache 6.8% (placebo 4.8%)
hypoglycaemia 6.8% (placebo 20.6%)
NCT02033889 · Phase 3
15 mg
urinary tract infection 6.4%
hypoglycaemia 5.7%
headache 4.4%
NCT01999218 · Phase 3
5 mg
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
headache 5.6%
NCT01999218 · Phase 3
15 mg
urinary tract infection 7.7%
hypoglycaemia 5.2%
nasopharyngitis 5.2%
NCT02099110 · Phase 3
5 mg
urinary tract infection 8%
hypoglycaemia 4.8%
nasopharyngitis 2.4%
NCT02099110 · Phase 3
15 mg + 100 mg
hypoglycaemia 8.2%
nasopharyngitis 4.9%
urinary tract infection 3.3%
NCT02099110 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.8%
nasopharyngitis 4.9%
hypoglycaemia 3.7%
NCT02099110 · Phase 3 · combination
15 mg
nasopharyngitis 3.9% (placebo 3.3%)
hypoglycaemia 3.3% (placebo 7.2%)
urinary tract infection 3.3% (placebo 5.2%)
NCT02036515 · Phase 3 · combination
5 mg
back pain 5.1% (placebo 3.9%)
nasopharyngitis 5.1% (placebo 3.3%)
hypoglycaemia 4.5% (placebo 7.2%)
NCT02036515 · Phase 3 · combination
15 mg + 100 mg
urinary tract infection 2.1% (placebo 1%)
hyperglycaemia 1% (placebo 6.2%)
blood glucose increased 0% (placebo 7.2%)
NCT02226003 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.1% (placebo 1%)
blood glucose increased 3.1% (placebo 7.2%)
hyperglycaemia 0% (placebo 6.2%)
NCT02226003 · Phase 3 · combination
15 mg
hypoglycaemia 20.6% (placebo 29.2%)
urinary tract infection 7.7% (placebo 9.7%)
upper respiratory tract infection 7.1% (placebo 4.5%)
NCT01986855 · Phase 3
5 mg
hypoglycaemia 31% (placebo 29.2%)
diarrhoea 6.3% (placebo 5.8%)
cough 5.7% (placebo 1.3%)
NCT01986855 · Phase 3
15 mg
hypoglycaemia 19.2% (placebo 12.7%)
nausea 15.4% (placebo 7.3%)
vomiting 15.4% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 14.3% (placebo 10.9%)
hypoglycaemia 11.1% (placebo 12.7%)
covid-19 7.9% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 11.5% (placebo 12.7%)
nausea 7.7% (placebo 7.3%)
vomiting 7.7% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
nausea 13.6% (placebo 7.3%)
abdominal pain 9.1% (placebo 5.5%)
diarrhoea 9.1% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
15 mg
hyperuricaemia 5.3% (placebo 12%)
hypoglycaemia 5.3% (placebo 1.2%)
nasopharyngitis 5.3% (placebo 6.6%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 5.3% (placebo 6.6%)
hypoglycaemia 3.5% (placebo 1.2%)
hyperuricaemia 2.9% (placebo 12%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
genital infection fungal 7.9% (placebo 0%)
athralgia 5.3% (placebo 0%)
nasopharyngitis 5.3% (placebo 0%)
NCT01096667 · Phase 2 · registry result, not featured evidence
25 mg
fatigue 5.1% (placebo 0%)
polyuria 5.1% (placebo 0%)
dizziness 2.6% (placebo 5.3%)
NCT01096667 · Phase 2 · registry result, not featured evidence
1 mg
musculoskeletal pain 5.1% (placebo 0%)
upper respiratory tract infection 2.6% (placebo 5.3%)
urinary tract infection 2.6% (placebo 2.6%)
NCT01096667 · Phase 2 · registry result, not featured evidence
5 mg
arthralgia 10.9% (placebo 1.9%)
headache 7.3% (placebo 3.7%)
hypoglycaemia 5.5% (placebo 0%)
NCT01059825 · Phase 2 · registry result, not featured evidence
25 mg
genital infection fungal 7.3% (placebo 1.9%)
diarrhoea 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
10 mg
urinary tract infection 9.1% (placebo 7.4%)
genital infection fungal 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
1 mg
arthralgia 3.7% (placebo 1.9%)
diarrhoea 3.7% (placebo 1.9%)
upper respiratory tract infection 3.7% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
15 mg Oral + 100 ug Oral
nasal congestion 12.5%
back pain 0%
headache 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg Oral + 100 ug IV
headache 25%
back pain 12.5%
nasal congestion 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg
decreased appetite 12.5%
headache 12.5%
tachycardia 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
15 mg
arthralgia 12.5%
back pain 12.5%
dizziness 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
4 mg Once Daily
diarrhoea 11.5%
headache 7.7%
abdominal pain 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Once Daily
headache 11.5%
constipation 3.8%
dizziness 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Twice Daily
abdominal pain 3.8%
diarrhoea 3.8%
dry mouth 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
1 mg Twice Daily
headache 12%
back pain 4%
dyspepsia 4%
NCT01054300 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 26 weeks versus 24 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation context differs: baseline_threshold differs (bmi>=18, hba1c<=10.5, hba1c>=7 versus bmi<=45); comorbidity_cardiovascular_disease differs (required versus none recorded).
  6. fTreatment context differs: combination versus monotherapy.
  7. gAssessment timepoints differ: 312 weeks versus 60 weeks.
  8. hPopulation comparability has not been reviewed for 13 of these studies.
  9. iPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bexagliflozin

HbA1c 7.0 or Less 0.14% (n=158) vs 0.03% (n=159) placebo @ 6wk20 mg
event count · % of participants
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
0.26% (n=158) vs 0.06% (n=159) placebo @ 12wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.26% (n=158) vs 0.1% (n=159) placebo @ 18wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.38% (n=158) vs 0.1% (n=159) placebo @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
36% (n=75) vs 15.3% (n=72) placebo @ 12wk*20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
22.2% (n=72) vs 15.3% (n=72) placebo @ 12wk*10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
21.1% (n=71) vs 15.3% (n=72) placebo @ 12wk*5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted

Ertugliflozin

MACE Plus 4.67 vs 4.92 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.42 vs 4.92 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Myocardial Infarction 2 vs 1.7 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
1.55 vs 1.7 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Total MACE 4.91 vs 4.59 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.35 vs 4.59 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
CV Death or HF Hospitalization Total 2.71 vs 3.42 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
2.92 vs 3.42 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 28.2% (n=2520) vs 15.5% (n=2527) placebo @ 18wk15 mg
responder rate · % of participants
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
29% (n=2347) vs 17.4% (n=2311) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
23.8% (n=1541) vs 16.6% (n=1496) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.7% (n=1578) vs 16.9% (n=1507) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.7% (n=860) vs 18.2% (n=786) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=529) vs 16.5% (n=478) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
21.1% (n=370) vs 10.7% (n=347) placebo @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.8% (n=54) vs 25% (n=48) placebo @ 18wk15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
32.7% (n=113) vs 12.8% (n=117) placebo @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8% (n=151) vs 13.1% (n=153) placebo @ 26wk15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
40% (n=205) vs 15.8% (n=209) placebo @ 26wk15 mg
NCT02033889 · Phase 3
36.6% (n=205) vs 30.6% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
33.7% (n=205) vs 19.1% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
31.9% (n=248) vs 32.8% (n=247) Sitagliptin @ 26wk15 mg
NCT02099110 · Phase 3
39.9% (n=153) vs 17% (n=153) placebo @ 26wk15 mg
NCT02036515 · Phase 3
32.7% (n=153) vs 13.7% (n=153) placebo @ 52wk15 mg
NCT02036515 · Phase 3
11.3% (n=97) vs 12.1% (n=99) placebo @ 26wk15 mg
NCT01986855 · Phase 3
40.8% (n=169) vs 16.2% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
28.4% (n=2544) vs 15.5% (n=2527) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.3% (n=2363) vs 17.4% (n=2311) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
23.9% (n=1570) vs 16.6% (n=1496) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
23.1% (n=1592) vs 16.9% (n=1507) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
24.9% (n=876) vs 18.2% (n=786) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.6% (n=526) vs 16.5% (n=478) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20.7% (n=348) vs 10.7% (n=347) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
32.7% (n=55) vs 25% (n=48) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
37% (n=100) vs 12.8% (n=117) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.2% (n=156) vs 13.1% (n=153) placebo @ 26wk5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.3% (n=207) vs 15.8% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
34.8% (n=207) vs 30.6% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
24.6% (n=207) vs 19.1% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
26.4% (n=250) vs 32.8% (n=247) Sitagliptin @ 26wk5 mg
NCT02099110 · Phase 3
32.1% (n=156) vs 17% (n=153) placebo @ 26wk5 mg
NCT02036515 · Phase 3
33.3% (n=156) vs 13.7% (n=153) placebo @ 52wk5 mg
NCT02036515 · Phase 3
16.2% (n=105) vs 12.1% (n=99) placebo @ 26wk5 mg
NCT01986855 · Phase 3
38.2% (n=170) vs 16.2% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
42.9% (n=49) vs 15.6% (n=45) placebo @ 12wk5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
36.2% (n=47) vs 15.6% (n=45) placebo @ 12wk25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
49.2% (n=244) vs 32.8% (n=247) Sitagliptin @ 26wk15 mg + 100 mg
NCT02099110 · Phase 3 · combination
31.3% (n=96) vs 8.3% (n=96) placebo @ 26wk15 mg + 100 mg
NCT02226003 · Phase 3 · combination
38.6% (n=44) vs 15.6% (n=45) placebo @ 12wk10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
52.3% (n=243) vs 32.8% (n=247) Sitagliptin @ 26wk5 mg + 100 mg
NCT02099110 · Phase 3 · combination
35.7% (n=98) vs 8.3% (n=96) placebo @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
44% (n=50) vs 15.6% (n=45) placebo @ 12wk1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 6 5 8.8% (n=2520) vs 4.7% (n=2727) placebo @ 18wk15 mg
responder rate · % of participants
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
10.9% (n=2347) vs 6.1% (n=2311) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.6% (n=1541) vs 5.8% (n=1496) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8% (n=1578) vs 5.8% (n=1507) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.1% (n=860) vs 7.5% (n=786) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.5% (n=529) vs 6.5% (n=478) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2% (n=205) vs 2.9% (n=209) placebo @ 26wk15 mg
NCT02033889 · Phase 3
14.6% (n=205) vs 11% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
12.2% (n=205) vs 7.2% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
15.4% (n=169) vs 2.4% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
9% (n=2544) vs 4.7% (n=2727) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.4% (n=2363) vs 6.1% (n=2311) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2% (n=1570) vs 5.8% (n=1496) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.9% (n=1592) vs 5.8% (n=1507) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.1% (n=876) vs 7.5% (n=786) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.3% (n=526) vs 6.5% (n=478) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.7% (n=207) vs 2.9% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 11% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
10.6% (n=207) vs 7.2% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
14.7% (n=170) vs 2.4% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
20.4% (n=49) vs 6.7% (n=45) placebo @ 12wk5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
14.9% (n=47) vs 6.7% (n=45) placebo @ 12wk25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
13.6% (n=44) vs 6.7% (n=45) placebo @ 12wk10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
12% (n=50) vs 6.7% (n=45) placebo @ 12wk1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
Seated DBP -1.08 vs -0.12 placebo mmHg @ 18wk15 mg
absolute change · mmHg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
-0.95 vs -0.15 placebo mmHg @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.9 vs -0.23 placebo mmHg @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.92 vs -0.22 placebo mmHg @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.42 vs -0.64 placebo mmHg @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.43 vs -1.26 placebo mmHg @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.86 vs 7.29 placebo mmHg @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.64 vs -0.26 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.93 vs -2.91 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.92 vs -0.24 placebo mmHg @ 18wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.1 vs -0.72 placebo mmHg @ 26wk15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.19 vs 0.23 placebo mmHg @ 26wk15 mg
NCT02033889 · Phase 3
-1.19 vs 0.38 placebo mmHg @ 52wk15 mg
NCT02033889 · Phase 3
-1.52 vs -0.46 placebo mmHg @ 104wk15 mg
NCT02033889 · Phase 3
-2.36 vs -0.96 placebo mmHg @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.12 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.97 vs -0.15 placebo mmHg @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.94 vs -0.23 placebo mmHg @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.27 vs -0.22 placebo mmHg @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.45 vs -0.64 placebo mmHg @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.82 vs -1.26 placebo mmHg @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.18 vs 7.29 placebo mmHg @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.86 vs -0.26 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.18 vs -2.91 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.3 vs -0.24 placebo mmHg @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.52 vs -0.72 placebo mmHg @ 26wk5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.59 vs 0.23 placebo mmHg @ 26wk5 mg
NCT02033889 · Phase 3
-1.4 vs 0.38 placebo mmHg @ 52wk5 mg
NCT02033889 · Phase 3
-2.36 vs -0.46 placebo mmHg @ 104wk5 mg
NCT02033889 · Phase 3
-2.38 vs -0.96 placebo mmHg @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
-0.75 vs 0.3 placebo mmHg @ 4wk5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.71 vs 0.3 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-0.9 vs 0.3 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
eGFR -1.81 vs -0.03 placebo mL @ 18wk15 mg
absolute change · mL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
-1.18 vs -0.3 placebo mL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.35 vs -2.6 placebo mL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.3 vs -3.8 placebo mL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.93 vs -4.41 placebo mL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 placebo mL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.2 vs -1.8 placebo mL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.22 vs -0.03 placebo mL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.51 vs -0.3 placebo mL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.48 vs -2.6 placebo mL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -3.8 placebo mL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.75 vs -4.41 placebo mL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -6.8 placebo mL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7 vs -1.8 placebo mL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Serum Creatinine Change mg/dL 0.032 vs -0.002 placebo mg/dL @ 18wk15 mg
absolute change · mg/dL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
0.023 vs 0.004 placebo mg/dL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.034 placebo mg/dL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.049 placebo mg/dL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.036 vs 0.059 placebo mg/dL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.042 vs 0.098 placebo mg/dL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.001 vs -0.013 placebo mg/dL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.022 vs -0.002 placebo mg/dL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.013 vs 0.004 placebo mg/dL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.024 vs 0.034 placebo mg/dL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.037 vs 0.049 placebo mg/dL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.032 vs 0.059 placebo mg/dL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.027 vs 0.098 placebo mg/dL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.034 vs -0.013 placebo mg/dL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
UACR -14.71% (n=2450) vs 0% (n=2478) placebo @ 18wk15 mg
percent change · % of baseline
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 11 more results
-6.82% (n=2277) vs 5.41% (n=2257) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.06% (n=2084) vs 17.14% (n=2025) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.33% (n=1915) vs 27.03% (n=1841) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
21.25% (n=835) vs 50% (n=745) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=771) vs 48.53% (n=692) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.4% (n=2472) vs 0% (n=2478) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.53% (n=2306) vs 5.41% (n=2257) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.73% (n=2125) vs 17.14% (n=2025) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.33% (n=1933) vs 27.03% (n=1841) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.33% (n=825) vs 50% (n=745) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
30.99% (n=780) vs 48.53% (n=692) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2-hr Change mg/dL -3.47 vs 0.27 placebo mmol/L @ 26wk15 mg
absolute change · mmol/L
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -62.45 mg/dL as posted
show 1 more result
-3.56 vs 0.27 placebo mmol/L @ 26wk*5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -64.15 mg/dL as posted
Glycemic Rescue 1.5% (n=205) vs 17.7% (n=209) placebo @ 26wk15 mg
responder rate · % of participants
NCT02033889 · Phase 3
show 11 more results
1.5% (n=205) vs 17.2% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
10.7% (n=205) vs 24.4% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
2% (n=153) vs 16.3% (n=153) placebo @ 26wk15 mg
NCT02036515 · Phase 3
13.7% (n=153) vs 41.8% (n=153) placebo @ 52wk15 mg
NCT02036515 · Phase 3
0.6% (n=169) vs 9.6% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
2.9% (n=207) vs 17.7% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
4.3% (n=207) vs 17.2% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
11.1% (n=207) vs 24.4% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
1.3% (n=156) vs 16.3% (n=153) placebo @ 26wk5 mg
NCT02036515 · Phase 3
12.8% (n=156) vs 41.8% (n=153) placebo @ 52wk5 mg
NCT02036515 · Phase 3
1.2% (n=170) vs 9.6% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence

+ 26 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Ertugliflozin's landscape